TLDR
- Olema Pharmaceuticals (OLMA) surged 8.5% Monday following a narrow Q4 EPS beat, posting a $0.50 loss versus analyst expectations of $0.51.
- Q4 2025 saw a GAAP net loss of $46.1 million, while the full-year loss reached $162.5 million.
- Stifel maintained its Buy recommendation with a $48 price objective, highlighting cash reserves sufficient through mid-2028.
- Roche’s recent persevERA trial failure to meet its primary endpoint has created uncertainty around Olema’s OPERA-02 trial prospects.
- Wall Street maintains a “Moderate Buy” consensus with a $41 average price target, even as OLMA trades down 41% year-to-date despite a 234% annual surge.
Olema Pharmaceuticals (OLMA) experienced an 8.5% rally Monday following the release of fourth-quarter financial results that narrowly surpassed analyst projections. Shares reached an intraday peak of $16.07 before closing near $15.96, representing a solid advance from the previous closing price of $14.71.
Olema Pharmaceuticals, Inc., OLMA
The biotechnology firm disclosed a quarterly loss of $0.50 per share for Q4 2025, topping consensus forecasts calling for a ($0.51) loss by one cent. While the margin was slim, it proved sufficient to generate positive momentum.
Across the entirety of 2025, Olema registered a GAAP net loss totaling $162.5 million. The fourth quarter alone accounted for $46.1 million in losses. The company opted not to conduct an earnings conference call following the release.
The stock’s trajectory has been notably volatile despite the persistent losses. OLMA has delivered a 234% return over the trailing twelve months, yet surrendered 41% of its value year-to-date prior to Monday’s trading session.
Session volume registered at 518,220 shares — significantly beneath the typical daily average of approximately 1.6 million. The subdued volume suggests investors may be approaching the advance with measured caution.
Analyst Reaction
Stifel responded promptly to the earnings release, reaffirming its Buy recommendation alongside a $48 price objective. The firm highlighted Olema’s financial runway extending through mid-2028 as a crucial advantage, providing adequate resources to reach several critical milestones ahead of palazestrant’s anticipated commercial debut.
Palazestrant represents the company’s lead candidate for second- and third-line metastatic breast cancer treatment, with commercialization targeted for 2027.
The broader analyst community maintains an optimistic stance. Ten analysts currently assign Buy ratings to OLMA, with one Hold and one Sell rating. The consensus price target stands at $41.00 — representing substantial upside from present trading levels.
Oppenheimer reaffirmed its Outperform stance on March 9th. JPMorgan elevated its price objective from $29 to $32 last November while maintaining an Overweight rating. TD Cowen similarly holds a Buy recommendation, contending that palazestrant offers superior market exposure compared to rival therapies.
H.C. Wainwright reduced its target to $38 while preserving its Buy rating in response to recent clinical trial developments.
The Roche Factor
Earlier this month, Roche disclosed that its persevERA clinical study — assessing giredestrant in combination with palbociclib for first-line metastatic breast cancer — failed to achieve statistical significance on its progression-free survival primary endpoint. While numerical trends appeared favorable, the statistical miss carries significant implications.
The persevERA results are commonly interpreted as a potential indicator for Olema’s Phase 3 OPERA-02 study evaluating palazestrant. Top-line readouts from OPERA-02 aren’t anticipated before 2028 at the earliest.
Stifel noted that Roche’s complete persevERA dataset will likely be unveiled at ASCO 2026, potentially representing either a significant tailwind or challenge for OLMA shares.
Regarding financial positioning, Olema maintains a stronger cash position than debt burden, with a current ratio of 8.03. The 50-day moving average rests at $24.18, considerably above Monday’s price levels.
Institutional ownership accounts for 91.78% of outstanding shares. Corporate insiders have been net sellers recently — divesting approximately 805,501 shares valued at roughly $23 million during the past three months.
The company’s market capitalization currently stands at approximately $1.09 billion.
